THE EFFECT OF TREATING MULTI-RESISTANT TUBERCULOSIS ACCORDING TO IV/V CHEMOTHERAPY REGIMENS INCLUDING BEDAQUILINE

Tuberculosis as a social human disease has been known since ancient times. Morbidity and mortality from multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) both in RS(Y) and in the Russian Federation remain high.

In recent years, studies have been conducted on the effectiveness of chemotherapy using the drug bedaquiline. In the State Budgetary Institution of the Republic of Sakha (Yakutia) SPC “Phthisiology”, the prescription of bedaquiline to patients with MDR and XDR-TB in IV/V RCT started in 2019.

The purpose of the article is to evaluate the effect of treating multidrug-resistant tuberculosis with the inclusion of the drug bedaquiline in IV/V RCT in newly diagnosed patients with respiratory tuberculosis. The material and method of study were 80 patients with pulmonary tuberculosis with multiple and extensive drug resistance, determined by the method of drug susceptibility testing in nutrient media and molecular genetic methods. The article considers a social characteristic with a description of the clinical forms of pulmonary tuberculosis and the effectiveness of treatment. As a result, it was found that when the drug bedaquiline was included in the standard IV and V RCT regimen, there was a high efficiency of treatment in a short time with no undesirable side reactions. Statistical processing of the obtained data was carried out using statistical programs.

1. Vasil’eva I.A., Belilovskij E.M., Borisov S.E., Sterlikov S.A. Tuberkulez s mnozhestvennoj lekarstvennoj ustojchivost’yu vozbuditelya v stranah mira i v Rossijskoj Federacii. Tuberkulez i bolezni legkih. 2017, 95 (11): 5-17. https://doi.org/10.21292/2075-1230-2017-95-11-5-17.

2. CNIIOIZ/ Centr monitoringa po tuberkuleza/Analiticheskie obzory/Situaciya po tuberkulezu v 2018 goda https://mednet.ru/images/materials/CMT/2018_god_tuberkulez_epidsituaciya.pdf

3. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicinskogo primeneniya Sirturo (Sirturo®). Registracionnyj nomer: LP-002281. [Elektronnyj resurs] URL: http://www.ros-med.info/reestrls/info.php?action=info&id=26223.

4. Ministerstvo zdravoohraneniya Rossijskoj Federacii. Tuberkulez u vzroslyh: Klinicheskie rekomendacii. 2020. Dostupno na: https://cr.minzdrav.gov.ru/schema/16_1/

5. Zhukova E.M., Vohminova L.G., Kudlaj D.A. Vliyanie sovremennoj himioterapii tuberkuleza s MLU/ SHLU na izmenenie u bol’nyh intervala QT na EKG. Tuberkulez i bolezni legkih. 2019;97(11):19–22. doi: 10.21292/2075-1230-2019-97-11-19-22.

6. Morozova T.I., Otpushchennikova O.N., Doktorova N.P., Danilov A.N. Opyt primeneniya preparata bedakvilin v lechenii bol’nyh tuberkulezom legkih s lekarstvennoj ustojchivost’

7. Gashev S. N. Matematicheskie metody v biologii: analiz biologicheskih dannyh v sisteme Statistica. – M.: YUrajt. 2020. 208 s.

8. Borisov S.E., Filippov A.V., Ivanova D.A., Ivanushkina T.N., Litvinova N.V., Garmash YU.YU. Effektivnost’ i bezopasnost’ osnovannyh na ispol’zovanii bedakvilina rezhimov himioterapii u bol’nyh tuberkulezom organov dyhaniya: neposredstvennye i okonchatel’nye rezul’taty. Tuberkulez i bolezni legkih. 2019;97(5):28–42. doi: 10.21292/2075-1230-2019-97-5-28-40.

9. Golubchikov P.N., SHCHegercov D.YU., Mel’nikova T.I., Krasnov D.V., Skvorcov D.A., Grishchenko N.G. Sluchaj uspeshnogo kombinirovannogo lecheniya bol’noj fibrozno-kavernoznym tuberkulezom legkih s shirokoj lekarstvennoj ustojchivost’yu. Tuberkulez i bolezni legkih. 2020;98(6):52–59. doi: 10.21292/20751230-2020-98-6-52-59.

10. Morozova T.I., Otpushhennikova O.N., Doktorova N.P., Danilov A.N. Opy`t primeneniya preparata bedakvilin v lechenii bol`ny`kh tuberkulezom legkikh s lekarstvennoj ustojchivost`yu vozbuditelya. Tuberkulez i bolezni legkikh. 2020;98(6):52–59. doi: 10.21292/2075-1230-2020-98-6-52-59.